Results 41 to 50 of about 4,432 (206)
Systematic Reviews, 2018 Background Previous research shows that many authors of Cochrane overviews were also involved in some of the included systematic reviews (SRs). This type of dual (co-)authorship (DCA) may be a conflict of interest and a potential source of bias.
Dawid Pieper +3 more
doaj +1 more source
Trials, 2021 Background Tonsillectomy is one of the most frequently performed surgeries in children and young adults worldwide. For decades, tonsillectomy was the surgical treatment of choice for recurrent acute tonsillitis. Tonsillotomy was used in some countries as
Orlando Guntinas-Lichius +4 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 3, March 2026.ABSTRACT Real‐world data (RWD) offers a valuable opportunity to access vast information that can drive research and generate real‐world evidence (RWE), offering insights into the actual delivery of care and patient outcomes beyond the limitations of traditional clinical trials.
Katharine Cresswell +12 more
wiley +1 more source
The Role of decision-analytic modelling in German health technology assessments [PDF]
, 2015 BACKGROUND: Decision-analytic modelling (DAM) has become a widespread method in health technology assessments (HTA), but the extent to which modelling is used differs among international HTA institutions.
Braun, Sebastian +3 more
core +2 more sources
Cancer, Volume 132, Issue 3, 1 February 2026.Abstract Background Event‐free survival (EFS) and complete response rate (CRR) are recommended as primary endpoints in bladder cancer trials to enable timely assessment of therapeutic benefit. However, their surrogacy relationship with overall survival (OS) in high‐risk non–muscle‐invasive bladder cancer (HR NMIBC) remains unclear.
Rituparna Bhattacharya +8 more
wiley +1 more source
Paying for "End-of-Life" Drugs in Australia, Germany, and the United Kingdom: Balancing Policy, Pragmatism, and Societal Values [PDF]
, 2012 Analyzes British, Australian, and German health systems' policies on covering expensive end-of-life drugs while maintaining equity and efficiency, such as requiring evidence of comparative clinical and cost-effectiveness.
Andreas Gerber +2 more
core
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward [PDF]
, 2016 List of regulatory documents organized per country and list of publications.
Alexandra Nolting +4 more
core +7 more sources
Cost‐Effectiveness Analysis of Risky Health Interventions: Moving Beyond Risk Neutrality
Ratio, Volume 38, Issue 4, Page 219-227, December 2025.ABSTRACT Cost‐effectiveness analysis for health interventions is traditionally conducted in a risk‐neutral way, insensitive to risk attitudes in the population, which are potentially non‐neutral. While the standard outcome metric of quality‐adjusted life years (QALYs) aims to be deferential to people's valuations of health states, cost‐effectiveness ...
Johanna Thoma
wiley +1 more source
Effects of treatment in women with gestational diabetes mellitus : systematic review and meta-analysis [PDF]
, 2010 Objective: To summarise the benefits and harms of treatments for women with gestational diabetes mellitus. Design: Systematic review and meta-analysis of randomised controlled trials.
Horvath, Karl +7 more
core +1 more source
Knee Surgery, Sports Traumatology, Arthroscopy, Volume 33, Issue 11, Page 3739-3743, November 2025.Abstract Orthopaedic trials frequently rely on patient‐reported outcomes (PROs) to measure primary end points. Thresholds for clinically meaningful score differences are then used to interpret PRO scores and support result interpretation. At the patient level, thresholds are used to determine if an individual patient has experienced a clinically ...
David F. Hamilton +2 more
wiley +1 more source